{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:22:56Z","timestamp":1773289376720,"version":"3.50.1"},"reference-count":106,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2023,9,2]]},"DOI":"10.1080\/17425255.2023.2260305","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:41:07Z","timestamp":1694828467000},"page":"617-633","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"19","author":[{"given":"Magdalena","family":"Witkowska","sequence":"first","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Majchrzak","sequence":"additional","affiliation":[{"name":"Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-5415","authenticated-orcid":false,"given":"Pawe\u0142","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-2098","authenticated-orcid":false,"given":"Anna","family":"Wolska-Washer","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland"},{"name":"Department of Hematology, Medical University of Lodz, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041720"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21595"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10113"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.208"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18075"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1384814"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030771"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.296.5573.1655"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694853"},{"key":"e_1_3_5_18_1","first-page":"1","article-title":"Is this the end for immunochemotherapy in relapsed\/refractory chronic lymphocytic leukemia?","volume":"10","author":"Robak T","year":"2023","unstructured":"Robak T. Is this the end for immunochemotherapy in relapsed\/refractory chronic lymphocytic leukemia? Leuk Lymphoma. 2023;10:1\u20133.","journal-title":"Leuk Lymphoma"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc839"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00209-1"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pathol.4.110807.092311"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0954-x"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091962"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3860"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704357200"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200408005"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00357"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers2031576"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1879"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-019-0129-z"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(99)80029-5"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008101"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010590200"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0474"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1056"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.31.19236"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2926"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11309"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121801"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061571"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.419"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11309"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133087"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005627"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-454439"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0304-0"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.634683"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.361"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.5572.5572"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.495"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281266"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538546"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-709519"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630947"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01460"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.008"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1013-4"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00915"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020069"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0881"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25243"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0031"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01010-6"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25634"},{"key":"e_1_3_5_73_1","unstructured":"FDA. FDA warns about possible increased risk of death and serious side effects with cancer drug copiktra (duvelisib). News Release. FDA. [2022 Jun 30; cited 2022 Sep 26]. Available from: https:\/\/bit.ly\/3PAlZLl."},{"key":"e_1_3_5_74_1","volume-title":"Presented in: Proceedings of the Society of Hematologic Oncology 2019 Annual Meeting","author":"Flinn IW","unstructured":"Flinn IW, Montillo M, Ill\u00e9s A, et al. Effect of dose modifications on responses to duvelisib in patients with relapsed\/refractory (R\/R) CLL\/SLL in the DUO trial. Presented in: Proceedings of the Society of Hematologic Oncology 2019 Annual Meeting; 2019 Sep 11-15; Houston (Texas). Clin Lymph.Myeloma Leuk. (2019) 19, Supplement 1, Abstract CLL-029."},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0838-6"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw282"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.12.003"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25711"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1034253"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30082-2"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03433"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134783"},{"key":"#cr-split#-e_1_3_5_84_1.1","unstructured":"FDA. FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma. FDA. [Updated 2021 Feb 5"},{"key":"#cr-split#-e_1_3_5_84_1.2","unstructured":"cited 2022 Nov 3]. Available from: https:\/\/bit.ly\/3Dxwg6A"},{"key":"e_1_3_5_85_1","unstructured":"FDA. FDA withdrew its approval for the cancer medicine ukoniq (umbralisib) due to safety concerns. FDA. Drug Safety Podcast. [2022 Jul 7; cited 2022 Nov 15]. Available from: https:\/\/bit.ly\/3FC651c"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.09.006"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03450-5"},{"key":"e_1_3_5_88_1","unstructured":"Zandelisib (ME-401) in subjects with follicular lymphoma or marginal zone lymphoma after failure of two or more prior therapies (TIDAL). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03768505"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148015"},{"key":"e_1_3_5_90_1","unstructured":"Gormeley N FDA introductory comments. Oncologic Drugs Advisory Committee Meeting. [2022 Apr 21; cited 2022 Nov 20]. Available from: https:\/\/bit.ly\/3Sfivyo"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-867499"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147867"},{"key":"e_1_3_5_93_1","unstructured":"News release. Incyte. [2022 Jan 25; cited 2022 Jan 26]. Available from: https:\/\/bit.ly\/3r3EqhQ"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12527"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.4.2236"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169656"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136031"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082293"},{"key":"e_1_3_5_99_1","volume-title":"Proceedings of the Annual Meeting of the American Association for Cancer Research 2020","author":"Yang X","year":"2020","unstructured":"Yang X, Yang X, Cui X, et al. BGB-10188, a highly selective PI3K\u03b4 inhibitor with improved safety profile and superior anti-tumor activities in vivo. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 664."},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01140-z"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-5454"},{"issue":"5","key":"e_1_3_5_102_1","first-page":"V488","article-title":"A phase I study of HMPL-689, a selective oral phosphoinositide 3- kinase-delta inhibitor, in patients with relapsed or refractory lymphoma.Abstract 1107TiP","volume":"30","author":"Cohen J","year":"2019","unstructured":"Cohen J, Mascunano RC, Ferreri AJM, et al. A phase I study of HMPL-689, a selective oral phosphoinositide 3- kinase-delta inhibitor, in patients with relapsed or refractory lymphoma.Abstract 1107TiP. Ann Oncol. 2019;30(Suppl 5):V488.","journal-title":"Ann Oncol"},{"issue":"5","key":"e_1_3_5_103_1","first-page":"S777","article-title":"A phase Ib study result of HMPL-689, a PI3Kdinhibitor, in Chinese patients with relapsed\/refractory lymphoma. Abstract 833O","volume":"32","author":"Cao J","year":"2021","unstructured":"Cao J, Li Z, Zhou J, et al. A phase Ib study result of HMPL-689, a PI3Kdinhibitor, in Chinese patients with relapsed\/refractory lymphoma. Abstract 833O. Ann Oncol. 2021;32(Suppl 5):S777.","journal-title":"Ann Oncol"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-683516"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30028-5"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633156"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591577"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2023.2260305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T15:50:59Z","timestamp":1727279459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2023.2260305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":106,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,2]]}},"alternative-id":["10.1080\/17425255.2023.2260305"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2023.2260305","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}